TidalSense AI Healthtech Raises $19M for Lung Disease Diagnosis

London, UK – TidalSense, a pioneering UK-based health technology firm, has successfully closed a significant funding round, securing $19 million to accelerate the adoption of its artificial intelligence-driven diagnostic tool for respiratory conditions. This latest infusion of capital, led by new entrant Cross-Border Impact Ventures, a Canadian healthtech impact fund, alongside continued support from existing backers BGF, Airstream Capital, and Foresight Group, will fuel the expansion of its innovative N-Tidal Diagnose platform across the NHS and into European and US markets.

The company's proprietary technology aims to dramatically reduce the diagnostic timeline for Chronic Obstructive Pulmonary Disease (COPD), a debilitating condition affecting nearly two million individuals in the UK and contributing to approximately 30,000 deaths annually. Traditionally, diagnosing COPD can be a lengthy process, often taking up to an hour and requiring specialized equipment and trained personnel. TidalSense's AI solution, however, analyzes a patient's CO₂ waveform captured through a simple, handheld device during a brief 75-second breathing exercise. The AI models, trained on an impressive dataset exceeding 2.5 million patient breaths, can then identify COPD in under five minutes.

This efficiency gain is a critical advancement in respiratory care. TidalSense estimates that its system allows clinicians to assess four to six patients per hour, a substantial increase compared to the roughly one patient per hour typically managed with conventional spirometry. This enhanced throughput is particularly vital given COPD's significant burden on the UK's National Health Service, which incurs an estimated £1.9 billion annually in costs associated with the disease. The platform's ease of use, requiring only about 10 minutes of training for healthcare professionals, further democratizes access to rapid diagnosis.

Founded in 2013 by CEO Dr. Ameera Patel, whose personal experience with delayed diagnosis inspired the venture, TidalSense has now amassed a total of $40 million, including prior grant funding. The company's mission is to bridge the diagnostic gap, particularly for underserved communities, by providing accessible and swift testing solutions. The recent funding will be instrumental in scaling its operations, expanding its presence within the NHS where it began trials last year, and establishing a foothold in key international healthcare markets.

The healthtech sector continues to see robust investor interest, particularly in solutions that leverage AI to improve patient outcomes and operational efficiency. The global AI in healthcare market is projected to grow substantially, with various reports indicating a compound annual growth rate exceeding 30% in the coming years. TidalSense's focus on a prevalent and costly condition like COPD positions it to capture a significant share of this expanding market, offering a compelling value proposition for healthcare providers seeking to optimize diagnostic pathways and improve patient care.

The implications of TidalSense's technology extend beyond mere time savings. By enabling earlier and more accurate detection of COPD, the platform has the potential to facilitate timely interventions, potentially slowing disease progression and improving the quality of life for millions. The company's strategic expansion into the US market, a significant global healthcare spending hub, represents a key growth vector following its successful European rollout.